These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21333336)

  • 1. Impact of prostate gland volume on cryoablation prostate-specific antigen outcomes.
    Levy DA; Jones JS
    Urology; 2011 Apr; 77(4):994-8. PubMed ID: 21333336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of disease burden on cryoablation prostate-specific antigen outcomes.
    Levy DA; Li J; Jones S
    Urology; 2010 Feb; 75(2):478-81. PubMed ID: 19963251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of initial prostate-specific antigen levels after salvage cryoablation for prostate cancer.
    Levy DA; Pisters LL; Jones JS
    BJU Int; 2010 Oct; 106(7):986-90. PubMed ID: 20230388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease burden predicts for favorable post salvage cryoablation PSA.
    Levy DA; Li J; Jones JS
    Urology; 2010 Nov; 76(5):1157-61. PubMed ID: 20381837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry.
    Jones JS; Rewcastle JC; Donnelly BJ; Lugnani FM; Pisters LL; Katz AE
    J Urol; 2008 Aug; 180(2):554-8. PubMed ID: 18550117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary cryoablation nadir prostate specific antigen and biochemical failure.
    Levy DA; Pisters LL; Jones JS
    J Urol; 2009 Sep; 182(3):931-7. PubMed ID: 19616226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The independent impact of extended pattern biopsy on prostate cancer stage migration.
    Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
    J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of initial prostate-specific antigen levels after salvage cryoablation for prostate cancer.
    Ismail M; Sood A; Davies J
    BJU Int; 2011 Mar; 107(6):1010; author reply 1010. PubMed ID: 21392215
    [No Abstract]   [Full Text] [Related]  

  • 9. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer.
    Lambert EH; Bolte K; Masson P; Katz AE
    Urology; 2007 Jun; 69(6):1117-20. PubMed ID: 17572198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryoablation as primary treatment for localized prostate cancer followed by penile rehabilitation.
    Ellis DS; Manny TB; Rewcastle JC
    Urology; 2007 Feb; 69(2):306-10. PubMed ID: 17320669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cryoablation: prospective analysis comparing high- and low-risk prostate cancer outcomes.
    El Hayek OR; Alfer W; Reggio E; Pompeo AC; Arap S; Lucon AM; Srougi M
    Urol Int; 2008; 81(2):186-90. PubMed ID: 18758217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between serum prostate specific antigen level and tumor volume persists in the current era.
    Ochiai A; Troncoso P; Babaian RJ
    J Urol; 2007 Mar; 177(3):903-6. PubMed ID: 17296372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage prostate cryoablation: initial results from the cryo on-line data registry.
    Pisters LL; Rewcastle JC; Donnelly BJ; Lugnani FM; Katz AE; Jones JS
    J Urol; 2008 Aug; 180(2):559-63; discussion 563-4. PubMed ID: 18554664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base.
    Freedland SJ; Kane CJ; Presti JC; Terris MK; Amling CL; Dorey F; Aronson WJ
    J Urol; 2003 Mar; 169(3):969-73. PubMed ID: 12576824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy.
    Lerner SE; Blute ML; Bergstralh EJ; Bostwick DG; Eickholt JT; Zincke H
    J Urol; 1996 Jul; 156(1):137-43. PubMed ID: 8648775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
    Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Frank I; Blute ML
    BJU Int; 2008 Feb; 101(3):299-304. PubMed ID: 17922854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
    Swindle P; Eastham JA; Ohori M; Kattan MW; Wheeler T; Maru N; Slawin K; Scardino PT
    J Urol; 2005 Sep; 174(3):903-7. PubMed ID: 16093984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
    Graefen M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Palisaar J; Huland E; Scardino PT; Kattan MW; Huland H
    J Urol; 2002 Mar; 167(3):1306-9. PubMed ID: 11832719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.